Greetings, advocates! This month’s Washington update covers how Congress’s tax proposals affect rheumatology, the ACR’s plan to fight Medicare’s adjustments to Part B drug costs in MIPS, the good news of Medicare’s new individualized biosimilar reimbursement, advances in the rheumatology-specific Alternative Payment Model and developments in Congress’s awareness about the perilous pharmacy benefit manager system….
Search results for: biosimilars
Trump Administration Proposes Medicare Rules Aimed at Opioids, Drug Costs
(Reuters)—The Trump administration on Thursday proposed changes to Medicare drug plans including limits on opioid prescriptions and rules aimed at reducing drug costs for seniors, such as requiring health insurers to pass on discounts to consumers. To help combat overprescription and abuse of addictive painkillers, the U.S. Centers for Medicare and Medicaid Services (CMS) said…
Year in Review: The ACR Advances Education, Rheumatic Disease Awareness, Strategic Planning in 2017
It seems like yesterday I was asked to write my first presidential column, and here I am penning my last. It’s incredible how fast the time goes and yet how much gets done. That progress is made possible by the dedicated and talented group of ACR volunteers and staff. This year, the College has had…
Keeping the Pressure on Congress: ACR Opposes Medicare Payment Adjustment Plan, Executive Order
Greetings, advocates! Here’s a brief, interim hodgepodge of updates to keep you posted on government advocacy before the deluge of information swamps you in San Diego. The Next Big Thing: Part B Drug Reimbursements Medicare currently plans to adjust reimbursement of doctors in the MIPS program in 2019, not only based on E/M office services,…
Report on EU’s Experience with Biosimilar Drugs Released: Will U.S. Experience Be Similar?
As questions about biosimilar medications swirl among U.S. rheumatologists, a recently released report sheds some light on the European experience with biosimilars—and may offer some important insights for the U.S. market. The report, Biosimilars in the EU: Information Guide for Healthcare Professionals, was released in late April by the European Medicines Agency (EMA) and the…
Pfizer Files Suit Against J and J over Remicade Contracts
(Reuters)—Drugmaker Pfizer Inc on Wednesday filed a lawsuit against Johnson and Johnson, saying its rival’s contracts with health insurers for blockbuster rheumatoid arthritis drug, Remicade, were anticompetitive and blocked sales of Pfizer’s new biosimilar. Pfizer said in the suit that Johnson and Johnson is offering discounts on its Remicade treatment in exchange for essentially excluding…
ARHP Stands Up for Members and Patients
Editor’s note: The new Pillar Talk column is developed by the ARHP Executive Committee in an effort to share information about ongoing activities related to our four pillars: Education, Practice, Research and Advocacy. ARHP volunteers are actively involved in the ACR’s efforts to advocate for the care of our patients and the rheumatology professionals who…
RheumPAC: Answers to FAQs
What is RheumPAC? RheumPAC is the ACR’s nonpartisan political action committee (PAC) that works to elect and support pro-rheumatology candidates. It is the only PAC dedicated to the interests of the rheumatology profession. RheumPAC was created 10 years ago with the mission of educating, electing and supporting federal lawmakers who understand and can positively address…
FDA Approves First Biosimilar for the Treatment of Cancer
Mvasi, a biosimilar to the cancer drug Avastin, is approved for certain colorectal, lung, brain, kidney and cervical cancers The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment…
N.Y. Rheumatologist Makes Advocacy a Priority
In 2005, not long after he became a private practice rheumatologist on Long Island, N.Y., Howard Blumstein, MD, dipped his toe into the advocacy pool at the encouragement of his partner, Max Hamburger, MD. “I thought it would be interesting to learn more about the issues that affect our patients and our practices, and I…
- « Previous Page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- …
- 32
- Next Page »